Stockreport

The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran

MEDICINES  (MDCO) 
Last medicines earnings: 10/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: themedicinescompany.com/investors
PDF ­ ORION-11 study met all primary and secondary efficacy endpoints with efficacy consistent with Phase 1 and 2 studies­ Safety profile of inclisiran was at least as favor [Read more]